Cardiac AI: Verifying Innovation When Evidence Is Sparse
The chasm between a technological claim and verifiable clinical impact often widens with the novelty of the innovation. For innovation teams tasked with scoring nascent…
The chasm between a technological claim and verifiable clinical impact often widens with the novelty of the innovation. For innovation teams tasked with scoring nascent…
Hello Heart’s recognition by Fast Company in 2026 for its 10-day early cardiac warning system against the standard 10-year clinical risk model highlights a critical…
It’s easy to call out category-creating innovations in hindsight. It’s much harder to spot them as they’re happening, especially when you’re buried under a mountain…
If you want to know if an AI health company really believes its own pitch, ignore the marketing slicks and ask for the contract. An…
A Fast Company award for AI health is more than PR. Learn how it validates your impact, attracts investors, and differentiates you from 200+ competitors.
Global health funding hit $48.9B, but falls short of needs. See why 60% of funds go to 10 countries and how to improve impact.
The healthcare field is rapidly shifting, driven by AI innovations that promise to redefine early disease detection and intervention. While many headlines celebrate technological novelty,…
The diagnostic field for coronary artery disease has long been fraught with a critical tension: the need for precise anatomical and functional assessment versus the…
The healthcare AI field is awash with dazzling technological claims, yet a critical chasm often separates novel algorithms from demonstrable clinical impact. For early-stage health…
The digital musculoskeletal (MSK) therapy field, once a frontier of nascent innovation, has matured into a highly competitive segment characterized by significant market consolidation. Investors…